Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
This study has been terminated.
(Pharmaceutical company no longer manufacturing investigational product.)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
First received: September 9, 2010
Last updated: January 7, 2015
Last verified: September 2013
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma
Primary Outcome Measures:
- Objective Response Rate [ Time Frame: Following two 3-week cycles ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||September 2013 (Final data collection date for primary outcome measure)
Experimental: Genasense + Paclitaxel + Carboplatin
Genasense 900 mg by vein over 1 hour on days 1, 3, and 5 of a 21 day cycle. Paclitaxel 175 mg/m2 by vein over 1 hour on day 3 of a 21 day cycle. Carboplatin (AUC= 6) mg by vein over 30 minutes on day 3 of a 21 day cycle.
900 mg by vein over 1 hour on days 1, 3, and 5 of a 21 day cycle.
175 mg/m2 by vein over 1 hour on day 3 of a 21 day cycle.
Other Name: Taxol
(AUC= 6) mg by vein over 30 minutes on day 3 of a 21 day cycle.
Other Name: Paraplatin
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients must have a history of uveal melanoma and documented metastatic disease
- Patients must have at least one measurable lesion as per revised RECIST Criteria. A measurable lesion is defined as a non-nodal lesions that is >/= 10 mm provided the CT slice is </=5 mm in thickness or a pathologic lymph node that is >/= 15 mm on the short axis provided the CT slice is </= 5 mm in thickness or Superficial skin lesion that is >/= 10 mm in diameter as assessed using calipers. Bone lesions are not considered measurable.
- Patients may be previously untreated or may have received prior systemic therapy but no more than one systemic cytotoxic chemotherapy regimen and one targeted therapy for metastatic disease.
- At least 6 weeks (42 days) since any prior immunotherapy, cytokine, biologic, vaccine or other therapy unless patients have progressed during therapy. If progression occurred during therapy, patient must have recovered from any side effects before starting GCP therapy.
- At least 4 weeks (28 days) since prior radiotherapy to > 20% of the bone marrow.
- Lesions being used to assess disease status may not have been radiated or if so, must have progressed during or after radiation therapy.
- Patients must have ECOG performance status of 0 - 2.
- Patients should be 18 years of age or older.
- Patients must have adequate liver and renal function as defined by total bilirubin </=1.5 mg/dl, serum Lactate Dehydrogenase level no higher than 2.0 x UNL of the institution, transaminase (i.e., ALT and AST) levels no higher than 5 x UNL and serum creatinine </=1.5 mg/dl or estimated Creatinine Clearance >/=60 ml/min
- Patients must have adequate bone marrow function as defined by an absolute neutrophil count of greater or equal to 1,500/mm3, and platelet count of greater or equal to 100,000/mm3.
- Patients must sign an informed consent form indicating that they are aware of the investigational nature of this study and in keeping with the policies of the institution.
- Females of childbearing potential (non childbearing is defined as greater than one year post-menopausal or surgically sterilized) must use acceptable contraceptive methods (abstinence, intrauterine device, oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 7 days prior to beginning treatment on this trial. Sexually active men must also use acceptable contraceptive methods for the duration of time on study.
- Patients who have received prior therapy with Genasense, any taxane or any of cisplatin analogues for systemic disease.
- Patients whose site of primary melanoma is not in the choroid.
- Patients who have a current history of neoplasm other than the entry diagnosis, except for curatively treated non-melanoma skin cancer or carcinoma in situ of the prostate or cervix or other cancers treated for cure and with a disease-free survival longer than 2 years.
- Patients with brain metastasis or history of brain metastasis (es).
- Patients who are pregnant or breastfeeding.
- Patients with current active infections requiring anti-infectious treatment (e.g., antibiotics, antivirals, or antifungals).
- Patients with current peripheral neuropathy of any etiology that is greater than grade one (1).
- Patients with unstable or serious concurrent medical conditions are excluded. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent. PI or his designee shall make the final determination regarding appropriateness of enrollment.
- Patients with a known hypersensitivity to cremophor containing anti-cancer agents.
- Patients with one or more of the following as the only manifestations of disease are ineligible: Osteoblastic bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, carcinomatous lymphangitis, CNS metastases, lesions in a previously irradiated area that have not shown definite progression, or disease only inferred from laboratory tests or markers.
- Patients with Gilbert's Syndrome.
- Patients must not have had major surgery within the past 14 days.
- Patients must not receive any concurrent chemotherapy, radiotherapy, or immunotherapy while on study.
- Known HIV disease or infection.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01200342
|UT MD Anderson Cancer Center
|Houston, Texas, United States, 77030 |
M.D. Anderson Cancer Center
||Sapna P. Patel, MD
||UT MD Anderson Cancer Center
No publications provided
||M.D. Anderson Cancer Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 9, 2010
||January 7, 2015
||United States: Food and Drug Administration
Keywords provided by M.D. Anderson Cancer Center:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 30, 2015
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action